CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OBI Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OBI Pharma Inc
19F
No.3, Yuanqu Street, Nangang District
Phone: +886 226558799p:+886 226558799 TAIPEI, 115  Taiwan Ticker: 41744174
Business Summary
OBI Pharma Inc is a Taiwan-based cancer drug company, primarily engaged in the research and development of new drugs related to cancer. The Company focuses on innovation and development of cancer therapies, with a product pipeline that includes new Antibody-Drug Conjugate (ADC) products targeting TROP2, Nectin4, HER2, and dual-antigen targets. The Company also possesses proprietary ADC enabling technologies, including GlycOBI, GlycOBI DUO, EndoSymeOBI, ThiOBI, and HYPrOBI. All products in the Company’s pipeline are currently in the research and development stage, and several have entered human clinical trials.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Kung-YeeLiang 12/29/2023 12/21/2023
Chief Executive Officer, Director HeidiWang 79 6/27/2025 6/2/2023
Chief Operating Officer, Corporate Governance Officer, Head of Finance ColinKao 8/2/2024 3/13/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
4174
TH-3424

General Information
Number of Employees: 40 (As of 12/31/2012)
Outstanding Shares: 262,968,000 (As of 9/30/2025)
Shareholders: 37,847
Stock Exchange: TPO
Fax Number: +886 226558798


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, November 23, 2025